NEWS RELEASES

Equity-based transaction with Winklevoss Capital activates 4.2 GSol/s of live, U.S.-based hashrate; approximately 18% of the Zcash network; Industry veteran Kevin Zhang joins as Head of Mining CAMBRIDGE, Mass., Aug. 18, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc.

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quarter ended June 30, 2026. "In the second quarter, Cypherpunk built upon the momentum established earlier this year through the…

Peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in 2L mCRC patients In DKK1 -high 2L mCRC patients, sirexatamab improved response, progression-free survival, and overall survival when added to bevacizumab…

Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1 -high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1 -high CRC patients CAMBRIDGE, Mass., Oct.

CAMBRIDGE, Mass., Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has closed its previously announced private placement led by Winklevoss Capital raising $58,888,888…

CAMBRIDGE, Mass., Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in cash commitments for a private investment in public equity ("PIPE") offering led by…